Clinical trials: Relapsing-Remitting
Relapsing-Remitting Multiple Sclerosis
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of…
- Trial name
- NCT03284970
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
It is thought that treating multiple sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
- Trial name
- NCT00203073
- Testing
- glatiramer acetate 20 mg, glatiramer acetate 20 mg, with mitoxantrone
- Volunteers
- 40 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With RMS
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04032171
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing Remitting Multiple Sclerosis
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years.
- Trial name
- FILYRA (NCT06949956)
- Volunteers
- 140 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Relapsing Remitting Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with…
- Trial name
- NCT01037907
- Testing
- Pleneva TM BGC20-0134
- Where
- 35 sites in Belgium, France and 4 more
- Volunteers
- 173 people
- Sponsor
- Boston Scientific Corporation
Multiple Sclerosis
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week…
- Trial name
- DreaMS (NCT01226745)
- Testing
- ONO-4641
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 340 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or…
- Trial name
- OMS115102 (NCT00640328)
- Testing
- Ofatumumab 100, Ofatumumab 300, Ofatumumab 700
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
This is a study evaluating the effect on brain volume of daily glatiramer acetate (GA) and add-on pulse steroids.
- Trial name
- ASSERT (NCT00203047)
- Testing
- Glatiramer Acetate, Prednisone
- Volunteers
- 414 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Efficacy and Safety of BG00012 in MS
Determine the efficacy, safety, and tolerability of BG00012 in MS patients.
- Trial name
- NCT00168701
- Testing
- BG00012
- Where
- 42 sites in Czechia, Germany and 8 more
- Volunteers
- 260 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
The purpose of this study is to investigate the safety of subcutaneous (SC) interferon beta therapies with regard to frequency of injection site reactions (ISR) and flu-like symptoms (FLS) as reported by the relapsing-remitting…
- Trial name
- PERFECT (NCT03347370)
- Testing
- SC Peginterferon beta-1a, SC interferon beta-1a, SC interferon beta-1b
- Where
- Germany
- Volunteers
- 626 people
- Sponsor
- Biogen
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
The primary objective(s) of the study is to evaluate the impact of exposure to SC Peginterferon beta-1a or IM Interferon beta-1a before and during pregnancy on pregnancy outcome in female participants who had registered in the…
- Trial name
- NCT04655222
- Testing
- Interferon Beta Therapy
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of…
- Trial name
- CONFIRM (NCT00451451)
- Testing
- BG00012, Glatiramer Acetate
- Where
- 195 sites in United States, Belarus and 26 more
- Volunteers
- 1,417 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Dose-finding Study of MT-1303
The primary objectives of the study are: To evaluate the effects of three oral doses of MT-1303 compared to placebo given for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis (RRMS) on MRI parameters…
- Trial name
- NCT01742052
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 18 sites in Belgium, Bulgaria and 16 more
- Volunteers
- 415 people
- Sponsor
- Tanabe Pharma Corporation
Multiple Sclerosis
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
This extension study of was designed to evaluate the long-term safety, tolerability, and efficacy of fingolimod (FTY720) in patients with multiple sclerosis.
- Trial name
- NCT00662649
- Testing
- Fingolimod 0.5 mg, Fingolimod 1.25 mg
- Where
- 103 sites in Australia, Belgium and 20 more
- Volunteers
- 920 people
- Sponsor
- Novartis
Multiple Sclerosis, Relapsing-Remitting
Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis
This study aims to calibrate the Multiple Sclerosis Functional Composite (MSFC) for home implementation in a phase 2 trial of lisinopril in multiple sclerosis.
- Trial name
- NCT02369926
- Testing
- Multiple Sclerosis Functional Composite, Mobile Multiple Sclerosis Functional Composite
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Transparency Life Sciences
Relapsing-Remitting Multiple Sclerosis
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
This study is to find out if Interferon-beta can recover its effectiveness in patients with Multiple Sclerosis who have previously developed neutralizing antibodies to Interferon-Beta.
- Trial name
- RECOVER (NCT00492466)
- Testing
- Interferon-beta-1a, methylprednisolone
- Where
- Finland
- Volunteers
- 14 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab.
- Trial name
- TOPAZ (NCT02255656)
- Testing
- alemtuzumab GZ402673
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 1,062 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing Remitting Multiple Sclerosis
An Extension of the TG1101-RMS201 Trial
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT03381170
- Testing
- Ublituximab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- TG Therapeutics, Inc.